Cargando…
Clinical characteristics and management of headache in patients with myeloproliferative neoplasms
BACKGROUND: Headache is frequently reported as a neurological manifestation of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythaemia. This study sought to clarify the clinical characteristics and response to treatment of headaches in patients with MPNs. METH...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764390/ https://www.ncbi.nlm.nih.gov/pubmed/36561301 http://dx.doi.org/10.3389/fneur.2022.1051093 |
_version_ | 1784853264870670336 |
---|---|
author | Shimoyama, Takashi Yamaguchi, Hiroki Kimura, Kazumi Suzuki, Fumiaki Hayashi, Toshiyuki Wakita, Satoshi |
author_facet | Shimoyama, Takashi Yamaguchi, Hiroki Kimura, Kazumi Suzuki, Fumiaki Hayashi, Toshiyuki Wakita, Satoshi |
author_sort | Shimoyama, Takashi |
collection | PubMed |
description | BACKGROUND: Headache is frequently reported as a neurological manifestation of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythaemia. This study sought to clarify the clinical characteristics and response to treatment of headaches in patients with MPNs. METHODS: We prospectively studied 137 patients with MPNs. The following information was gathered to assess the features of headache at baseline and at follow-up (>6 months): (1) average duration of headache attacks, (2) number of headache days per month, (3) numerical rating scale (NRS), (4) Headache Impact Test-6 (HIT-6), and (5) Migraine Disability Assessment (MIDAS). We compared those parameters for headaches between the baseline and follow-up interviews according to the management. RESULTS: Thirty-seven (27.0%) patients had headache. The prevalence of headaches gradually decreased with increasing age (Age ≤ 49 years: 61.0%, 50–59 years: 38.5%, 60–69 years: 17.2%, 70–79 years: 5.1%, and ≥80 years: 0.0%, P < 0.001). Multiple logistic regression analysis showed that younger age, but not platelet counts or the JAK2 V617F mutation, was independently associated with headaches (Odds Ratios 2.004, 95% confidence intervals 1.293–3.108, P = 0.002). Scintillating scotomas were present in 22 (59.5%) of 37 patients with headaches, while four patients developed sudden headaches that lasted for only 0–10 min. Follow-up interviews were available for 31 (83.8%) of 37 patients with headaches. Twenty-one (67.7%) patients were treated with low-dose aspirin (100 mg once daily) [low-dose aspirin alone: n = 9; combined cytoreductive therapy: n = 12] for headache management. All parameters for headache [average duration of headache attacks, number of headache days per month, NRS score, HIT-6 score, and MIDAS score (all P < 0.001)] were significantly improved at follow-up in patients taking low-dose aspirin. However, there were no significant differences in these parameters of headaches in patients who did not receive low-dose aspirin. CONCLUSION: Headaches is common in patients with MPNs, particularly in younger patients. MPN-related headaches may be managed by using low-dose aspirin and controlling MPNs. |
format | Online Article Text |
id | pubmed-9764390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97643902022-12-21 Clinical characteristics and management of headache in patients with myeloproliferative neoplasms Shimoyama, Takashi Yamaguchi, Hiroki Kimura, Kazumi Suzuki, Fumiaki Hayashi, Toshiyuki Wakita, Satoshi Front Neurol Neurology BACKGROUND: Headache is frequently reported as a neurological manifestation of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythaemia. This study sought to clarify the clinical characteristics and response to treatment of headaches in patients with MPNs. METHODS: We prospectively studied 137 patients with MPNs. The following information was gathered to assess the features of headache at baseline and at follow-up (>6 months): (1) average duration of headache attacks, (2) number of headache days per month, (3) numerical rating scale (NRS), (4) Headache Impact Test-6 (HIT-6), and (5) Migraine Disability Assessment (MIDAS). We compared those parameters for headaches between the baseline and follow-up interviews according to the management. RESULTS: Thirty-seven (27.0%) patients had headache. The prevalence of headaches gradually decreased with increasing age (Age ≤ 49 years: 61.0%, 50–59 years: 38.5%, 60–69 years: 17.2%, 70–79 years: 5.1%, and ≥80 years: 0.0%, P < 0.001). Multiple logistic regression analysis showed that younger age, but not platelet counts or the JAK2 V617F mutation, was independently associated with headaches (Odds Ratios 2.004, 95% confidence intervals 1.293–3.108, P = 0.002). Scintillating scotomas were present in 22 (59.5%) of 37 patients with headaches, while four patients developed sudden headaches that lasted for only 0–10 min. Follow-up interviews were available for 31 (83.8%) of 37 patients with headaches. Twenty-one (67.7%) patients were treated with low-dose aspirin (100 mg once daily) [low-dose aspirin alone: n = 9; combined cytoreductive therapy: n = 12] for headache management. All parameters for headache [average duration of headache attacks, number of headache days per month, NRS score, HIT-6 score, and MIDAS score (all P < 0.001)] were significantly improved at follow-up in patients taking low-dose aspirin. However, there were no significant differences in these parameters of headaches in patients who did not receive low-dose aspirin. CONCLUSION: Headaches is common in patients with MPNs, particularly in younger patients. MPN-related headaches may be managed by using low-dose aspirin and controlling MPNs. Frontiers Media S.A. 2022-12-06 /pmc/articles/PMC9764390/ /pubmed/36561301 http://dx.doi.org/10.3389/fneur.2022.1051093 Text en Copyright © 2022 Shimoyama, Yamaguchi, Kimura, Suzuki, Hayashi and Wakita. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Shimoyama, Takashi Yamaguchi, Hiroki Kimura, Kazumi Suzuki, Fumiaki Hayashi, Toshiyuki Wakita, Satoshi Clinical characteristics and management of headache in patients with myeloproliferative neoplasms |
title | Clinical characteristics and management of headache in patients with myeloproliferative neoplasms |
title_full | Clinical characteristics and management of headache in patients with myeloproliferative neoplasms |
title_fullStr | Clinical characteristics and management of headache in patients with myeloproliferative neoplasms |
title_full_unstemmed | Clinical characteristics and management of headache in patients with myeloproliferative neoplasms |
title_short | Clinical characteristics and management of headache in patients with myeloproliferative neoplasms |
title_sort | clinical characteristics and management of headache in patients with myeloproliferative neoplasms |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764390/ https://www.ncbi.nlm.nih.gov/pubmed/36561301 http://dx.doi.org/10.3389/fneur.2022.1051093 |
work_keys_str_mv | AT shimoyamatakashi clinicalcharacteristicsandmanagementofheadacheinpatientswithmyeloproliferativeneoplasms AT yamaguchihiroki clinicalcharacteristicsandmanagementofheadacheinpatientswithmyeloproliferativeneoplasms AT kimurakazumi clinicalcharacteristicsandmanagementofheadacheinpatientswithmyeloproliferativeneoplasms AT suzukifumiaki clinicalcharacteristicsandmanagementofheadacheinpatientswithmyeloproliferativeneoplasms AT hayashitoshiyuki clinicalcharacteristicsandmanagementofheadacheinpatientswithmyeloproliferativeneoplasms AT wakitasatoshi clinicalcharacteristicsandmanagementofheadacheinpatientswithmyeloproliferativeneoplasms |